Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dihydroergotamine Clear all
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

NCT04940390
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine, Placebo
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
127
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Sep 13, 2026, 5:49 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma

NCT07665892
View directory record Official record
Conditions
Safety in Asthma Patients
Interventions
ASY202, Placebo
Combination Product
Lead sponsor
Aspeya, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Glendale, Arizona • Anaheim, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

NCT07226362
View directory record Official record
Conditions
Safety, and Tolerability
Interventions
DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg
Combination Product · Drug
Lead sponsor
Aspeya Switzerland SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT05337254
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine

NCT00335777
View directory record Official record
Conditions
Migraine
Interventions
Migranal nasal spray at 1 hour, Migranal nasal spray at 4 hour
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT03874832
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura, Migraine
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

NCT03901482
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine, Placebos
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
117
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 13, 2026, 5:49 AM EDT
Recruiting Not applicable Interventional

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

NCT03199651
View directory record Official record
Conditions
Cigarette Smoker, Current Smoker, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Best Practice, Biospecimen Collection, Laboratory Biomarker Analysis, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration, Smoking Cessation Intervention
Other · Procedure · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Recruiting Phase 2 Interventional

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

NCT07646613
View directory record Official record
Conditions
Migraine
Interventions
ASY202, Placebo
Combination Product
Lead sponsor
Aspeya, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
6
States / cities
Walnut Creek, California • Orlando, Florida • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

NCT01089062
View directory record Official record
Conditions
Healthy
Interventions
MAP0004, IV Placebo (Saline), Placebo Inhaler, IV Dihydroergotamine Mesylate (DHE)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 13, 2026, 5:49 AM EDT
Terminated Phase 2 Interventional Results available

Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

NCT03885154
View directory record Official record
Conditions
Migraine in Children
Interventions
Valproic Acid (VPA), Dihydroergotamine (DHE)
Drug
Lead sponsor
Kimberly S Jones
Other
Eligibility
10 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Not applicable Interventional Results available

A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity

NCT00203268
View directory record Official record
Conditions
Migraine
Interventions
dihydroergotamine mesylate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)

NCT03557333
View directory record Official record
Conditions
Migraine Headache
Interventions
INP104
Combination Product
Lead sponsor
Impel Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

NCT01191723
View directory record Official record
Conditions
Healthy
Interventions
MAP0004, Inhaler Placebo, Moxifloxacin, Placebo Capsule
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

NCT04406649
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
44
States / cities
Encino, California • Long Beach, California • Los Alamitos, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 13, 2026, 5:49 AM EDT